Orally-delivered monoclonal antibody

Class

Orally-delivered monoclonal antibody (gut-restricted; formulated for targeted release and receptor-mediated transport across inflamed intestinal mucosa; target antigen not publicly disclosed)

Notes

original target text: Orally-delivered monoclonal antibody (gut-restricted; formulated for targeted release and receptor-mediated transport across inflamed intestinal mucosa; target antigen not publicly disclosed)

This mechanism describes a delivery approach rather than a single molecular target: a monoclonal antibody (a lab-made protein designed to bind one specific molecule with high precision) formulated so it can be taken by mouth and act primarily within the gastrointestinal tract, rather than being injected and circulating throughout the body. Antibodies are ordinarily destroyed by stomach acid and digestive enzymes, and even if intact, they are too large to cross the intact intestinal lining efficiently. Gut-restricted oral formulations attempt to solve this by protecting the antibody until it reaches the intestine, then triggering release and using receptor-mediated pathways that become active in inflamed tissue to shuttle the antibody across the mucosal barrier locally. The biological rationale is to concentrate the therapeutic effect where disease activity is occurring, in conditions such as inflammatory bowel disease, while minimizing the antibody's presence in the bloodstream and other organs. If successful, this approach could combine the antigen specificity of biologic therapies with the convenience of an oral pill and a narrower systemic side-effect profile than an injected antibody with the same target. Because the specific antigen this antibody binds has not been disclosed, its precise downstream immunological effect cannot be described; the mechanism here is chiefly the physical strategy of local, oral biologic delivery.